Un portefeuille diversifié et complémentaire - ACHAT - OC 19€
En marge du congrès de l’American Association for Cancer Research (AACR), INNATE PHARMA organisait hier une conférence téléphonique afin de mettre en exergue les nombreuses publications présentées: IPH4301, un anti CD73 et un anti CD39 mais aussi de nouvelles données justifiant l’approche de la combinaison entre durvalumab d’AZN et monalizumab (IPH 2201), son anti NKG2A. Même si tous ces résultats ne devraient pas modifier significativement les attentes, ils démontrent surtout la capacité de la société à développer un pipeline innovant, et qui se renouvelle, dans la prise en charge du cancer. Les principaux composés présentés sont aujourd’hui considérés comme des options gratuites à notre thèse d’investissement bien qu’ils pourraient susciter des convoitises dans une logique de synergies avec d’autres checkpoints inhibiteurs. Nous maintenons notre recommandation à ACHAT avec un objectif de cours de 19€.Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.